We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Enzymatic Blood Test Could Detect Prediabetes

By LabMedica International staff writers
Posted on 20 Jul 2010
A pilot study reports that O-linked beta-N-acetylglucosamine (O-GlcNAc), an easy-to-detect enzyme in erythrocytes is up to two to three times higher in people with diabetes and pre-diabetes than in those with no disease.

Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA) studied blood samples from volunteers with no diabetes (36 samples), prediabetes (13 samples), and diabetes (53 samples), according to traditional tests that require patient fasting. More...
Erythrocyte proteins were then extracted from the samples, and the hemoglobins were depleted. Then, global O-GlcNAcylation (O-GlcNAc) of the proteins was confirmed by Western blotting using an O-GlcNAc-specific antibody. Relative O-GlcNAc transferase (OGT) and O-GlcNAcase--an enzyme that removes O-GlcNAc in red blood cells--protein amounts were similarly determined. The relative expression of O-GlcNAcase was then compared with the measured level of A1C.

The results showed that erythrocyte proteins are highly O-GlcNAcylated, and O-GlcNAcase expression is significantly increased in erythrocytes from both individuals with prediabetes and diabetes, compared with normal control subjects. However, unlike O-GlcNAcase, protein levels of OGT did not show significant changes. The researchers therefore suggest that the upregulation of O-GlcNAcase might be an adaptive response to hyperglycemia-induced increases in O-GlcNAcylation, which are likely deleterious to erythrocyte functions. The study was published in the July 2010 issue of Diabetes.

"This is an example of how basic research is directly affecting a serious disease,” said Gerald Hart, Ph.D., director of biological chemistry at the JHU School of Medicine. "The question was whether the elevation happened in the earliest stages of diabetes and therefore might have value as a diagnostic tool. Only a much larger clinical trial will determine if, by measuring O-GlcNAcase, we can accurately diagnose prediabetes.”

O-GlcNAc plays an important role in the development of insulin resistance and glucose toxicity, since it modifies many of the cell's proteins to control their functions in response to nutrients (such as glucose and lipids) and stress. O-GlcNAcylation is regulated by OGT, which attaches O-GlcNAc to serine and/or threonine residues of proteins, and by O-GlcNAcase, which removes O-GlcNAc. When the extent of O-GlcNAc attached to proteins becomes too high, as occurs in diabetes, it is harmful to the cell.

Related Links:

Johns Hopkins University




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.